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Abstract
Background: In addition to the regulation of blood pressure, α2- and β-adrenoceptor (AR)
subtypes play an important role in the modulation of noradrenergic neurotransmission in the
human CNS and PNS. Several studies suggest that the α2-AR responsiveness in cells and tissues
after chronic epinephrine (EPI) or norepinephrine (NE) exposure may vary, depending on the β-
AR activity present there. Recently, we reported that in BE(2)-C human neuroblastoma cells
(endogenously expressing α2A- and β2-AR), chronic EPI treatment (300 nM) produced a dramaticβ-adrenoceptor-dependent desensitization of the α2A-AR response. The aim of this study is to
determine if stable addition of a β2-AR to a second neuroblastoma cell line (SH-SY5Y), that
normally expresses only α2A-ARs that are not sensitive to 300 nM EPI exposure, would suddenly
render α2A-ARs in that cell line sensitive to treatment with the same EPI concentration.
Methods: These studies employed RT-PCR, receptor binding and inhibition of cAMP accumulation
to confirm α2-AR subtype expression. Stable clones of SH-SY5Y cells transfected to stably express
functional β2-ARs (SHβ2AR4) were selected to compare sensitivity of α2-AR to EPI in the presence
or absence of β2-ARs.
Results: A series of molecular, biochemical and pharmacological studies indicated that the
difference between the cell lines could not be attributed to α2-AR heterogeneity. We now report
that after transfection of functional β2-AR into SH-SY5Y cells (SHβ2AR4), chronic treatment with
modest levels of EPI desensitizes the α2A-AR. This effect results from a β2-AR dependent down-
regulation of native α2A-ARs by EPI accompanied by enhanced translocation of GRK2 and GRK3
to the membrane (required for GRK-mediated phosphorylation of agonist-occupied receptors).
Conclusion: This study further supports the hypothesis that the presence of the β-AR renders
the α2A-AR more susceptible to desensitization with physiological levels of EPI.
Published: 20 December 2007
BMC Pharmacology 2007, 7:16 doi:10.1186/1471-2210-7-16
Received: 8 June 2007
Accepted: 20 December 2007
This article is available from: http://www.biomedcentral.com/1471-2210/7/16
© 2007 Bawa-Khalfe et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 12
(page number not for citation purposes)
BMC Pharmacology 2007, 7:16 http://www.biomedcentral.com/1471-2210/7/16Background
Studying changes in α2-adrenoceptor (AR) signaling is
important for understanding the development and/or
manifestation for several CNS (cerebral ischemia, pain,
depression) and PNS disorders (hypertension and cardiac
dysfunction). Under physiological conditions, norepine-
phrine and epinephrine (NE and EPI, respectively) acti-
vate the α2-AR along with other members of the AR
family, which also includes α1- and β-ARs. The α2- and β-
ARs are often co-expressed on the same cell surface. Upon
activation by NE and EPI, the independent signals initi-
ated by the α2- and β-ARs often converge to regulate spe-
cific physiological endpoints such as insulin release [1],
maintenance of uterine smooth muscle tone [2], and
noradrenergic transmission in the CNS and PNS [3,4].
The α2- and β-ARs regulate many of these physiological
mechanisms by mediating opposing actions on adenylyl
cyclase; α2-AR inhibits while β-AR stimulates the adenylyl
cyclase pathway.
Continuous exposure to catecholamines leads to a declin-
ing receptor response, a phenomenon called desensitiza-
tion. The process of desensitization generally includes
receptor phosphorylation, internalization, and down-reg-
ulation. Unlike other members of the AR family, the α2A-
AR subtype does not readily down-regulate. Since this
subtype is the dominant α2-AR in the CNS and mediates
the "classical effects" of α2-ARs which include hypoten-
sion, sedation, and antinociception [5,6], numerous stud-
ies have focused on the regulatory mechanisms of the α2A-
AR. In cultured cell lines expressing either native α2A-AR
[7] or recombinantly over-expressed α2A-AR [8,9], supra-
physiological concentrations of EPI (100 μM) and NE (30
μM) were required to produce long-term α2A-AR desensi-
tization. The waning α2A-AR signal is attributed primarily
to down-regulation of the receptor and/or phosphoryla-
tion of the agonist occupied receptor by G-protein cou-
pled receptor kinases (GRK), specifically GRK2 and GRK3
[10,11]. Previous studies suggest that either of these two
α2A-AR desensitization mechanisms require supra-physio-
logical (μM) concentrations of agonist [10,12-14].
However, our recent studies in the BE(2)-C human neu-
roblastoma cell line suggest that when β-ARs are present
on the same cells lower, more physiologically relevant,
concentrations of EPI (300 nM) are able to desensitize the
α2A-AR following chronic (24 hr) treatment [15]. In the
absence of β-ARs, α2A-AR desensitization occurs only with
supra-physiological concentrations of EPI, if it occurs at
all [15]. Concurrent activation of the β-AR and α2A-AR
also prompts down-regulation of cell surface α2A-ARs
while specifically up-regulating the expression of GRK3
within BE(2)-C cells [15]. Enhanced GRK3 expression
plays a prominent role, as it is required for both β-AR-
dependent α2A-AR desensitization and down-regulation
[15,16]. Recently we reported similar findings for the α2B-
AR subtype in mouse neuroblastoma cells [17-19].
Since both α2- and β-ARs are often co-localized and share
the same endogenous ligands, it is reasonable that the
α2A-AR response is regulated differently in the presence
and absence of the β-AR. Indeed, evidence suggests that
the α2-AR responsiveness in cells and tissues after chronic
EPI or NE vary, depending on the β-AR activity present
there [2,15,20-23]. The aim of the present study is to com-
pare α2A-AR responsiveness after chronic EPI and NE treat-
ment in non-β-AR expressing (wild-type SH-SY5Y, wt)
human neuronal cells to α2A-AR responsiveness in SH-
SY5Y cells that have been stably transfected to express β2-
AR (SHβ2AR4). In doing so, we hope to determine
whether co-expression of the two ARs intrinsically pro-
duced this differential α2A-AR regulation and whether
enhanced expression of GRK3 is required for this regula-
tion.
Results
Characterization of the model system and establishment 
of the SHβ2AR4 cell line
Our first goal was to find a second model system that was
similar to the BE(2)-C human neuroblastoma cell line
(expressing modest levels of α2A-AR), but that didn't
express β-ARs. Kazmi and Mishra previously identified the
SH-SY5Y cell line as expressing two α2-AR binding sites
[24], while Parsley et al.[25] reported that it expressed a
single AR subtype, α2C, based upon functional and molec-
ular studies. Since receptor expression varies depending
on differentiation state and passage number, it was neces-
sary to determine which α2-AR subtypes were expressed in
our population of SH-SY5Y cells, using a combination of
binding, functional, and molecular approaches.
SH-SY5Y cells expressed α2-AR levels slightly greater than
the level detectable in BE(2)-C cells (Bmax: SH-SY5Y, 67.6
± 8.2 ; BE(2)-C, 40.8 ± 7.0 fmol/mg protein). According to
nonlinear and linear regression analysis of saturation
binding, the data best fit a single-site model in SH-SY5Y
cells, as observed previously in BE(2)-C cells. Rauwolscine
and yohimbine competed for specific [3H]rauwolscine
binding to SH-SY5Y cell membranes with higher affinity
than prazosin, the α2B/C-selective antagonist (Table 1;
[24]). Apparent Ki values of agonists and antagonists
against [3H]rauwolscine binding were determined for
comparison with previously reported values in cells
natively expressing α2A-, α2B, or α2C-ARs (HT29 and
BE(2)-C, NG108-15, OK; [15,26,27]) or cell lines express-
ing cloned α2C10, α2C2, and α2C4 [28]. Values obtained
from binding studies in SH-SY5Y cells correlated only to
values from BE(2)-C cells and showed the greatest similar-
ity with those derived from native and cloned α2A-AR-con-
taining cell membranes (Table 2). These results arePage 2 of 12
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in SH-SY5Y cells.
Functional studies were performed by measuring the abil-
ity of various α2-AR agonists to inhibit forskolin (10 μM)-
stimulated cAMP accumulation in intact cells. All α2-AR
agonists inhibited forskolin-stimulated cAMP accumula-
tion in a concentration-dependent manner; no stimula-
tion of cAMP accumulation was noted in the absence of
forskolin. Inhibition of cAMP accumulation by the α2-AR
agonist UK14,304 (30 nM; Fig. 1) was completely
reversed by 10 nM yohimbine, whereas the α2B/C-selective
antagonist ARC-239, at a concentration over 30-fold
higher than that of the agonist, failed to reverse the
actions of UK14,304. Thus, both binding and functional
data support the classification of the α2-AR subtype in this
neuroblastoma cell line as α2A.
Since Parsley et al.[25] were unable to detect α2A-AR RNA
by performing RT-PCR with total RNA extract, we opti-
mized our chances for detecting α2A-AR RNA by generat-
ing RT-PCR products from SH-SY5Y mRNA using primer
pairs selective for individual α2-AR subtypes (Table 3;
[29,30]) or a primer pair that recognizes two α2-AR recep-
tor subtypes distinguished by their restriction nuclease
digestion products (Table 3; [30]). RT-PCR with α2C10/
C4 primers gave a 233 bp product specific for α2A- andα2C-ARs; restriction digestion of this fragment with BglII,
that would specifically cleave α2A-AR, resulted in two frag-
ments of 117 bp and thereby established expression of
α2A-AR mRNA in SH-SY5Y cells. RT-PCR with α2C4 prim-
ers gave a 630 bp fragment, which was successfully
digested by BstXI to produce three fragments of 271, 225,
and 78 bp, consistent with the presence of an α2C-AR gene
product (Fig. 2). RT-PCR products were neither noted in
samples lacking reverse transcriptase (-), nor were they
produced with primers selective for α2C2 (α2B-AR; data
not shown). While SH-SY5Y cells express mRNA for both
α2A- and α2C-ARs, it appears that the predominant func-
tional α2-AR in our cell line is the α2A-AR.
Since these cells appear to express α2A-ARs with properties
similar to those in BE(2)-C cells [15] but lack a β-AR,
pcDNA 3.0 plasmid vector containing the human β2-AR
gene was transfected into SH-SY5Y cells. Colonies of sta-
ble transfectants were selected and maintained by their
resistance to G418 (600 μg/mL) and subsequently clonal
populations of β2-AR-expressing SH-SY5Y cells (SHβ2AR)
were screened for β-AR expression using [3H]CGP-12177
for binding studies as described in Methods. Since BE(2)-
C cells express very low levels of β2-AR (Bmax: 18.5 ± 6.2
fmol/mg protein), the SHβ2AR4 cell line that expressed
14.78 ± 4.19 fmol/mg protein of the β2-AR was selected
for the subsequent studies. To ensure that the β-ARs were
functional, the ability of isoproteranol (ISO) to stimulate
Table 1: Pharmacological characteristics of adrenoceptors in SH-
SH5Y and SHβ2AR4 cells.
SH-SY5Y SHβ2AR4
Agonist: log(Ki) log(EC50) log(EC50)
EPI -7.38 ± .04 -8.83 ± .06 -8.22 ± 0.21
UK 14,304 -7.38 ± .12 -7.22 ± .36 -7.72 ± 0.77
Oxymetazoline 
(OXY)
-8.85a -8.35 ± .47 N.D.
Isoproterenol N.A. N.A. -7.02 ± 0.28
Antagonist: log(Ki) Ki Ratio with OXY
Rauwolscine -8.82 ± .15 1.07 N.A
Yohimbine -8.56 ± .17 1.95 N.A
Prasozin -6.98a 74.4 N.A
Binding inhibition and cAMP accumulation studies were performed as 
described in Methods. The values of the apparent affinity constants 
Log(Ki) for each competitor were derived from their IC50 values (n = 
3–9) using the equation of Cheng and Prusoff [40]. The Log(EC50) 
values (concentration of the drug that produces 50% of the maximal 
inhibitory/stimulatory effect of that drug) were calculated by nonlinear 
regression analysis of the agonist concentration-response curves (n = 
3–9) of each agonist. aValues from Kazmi and Mishra [24]. N.D., not 
determined; N.A., not applicable.
Table 2: Correlation of SH-SY5Y cell α2-AR pKi values with those of native and cloned α2-AR subtypes.





v. HT29 21,22 6 0.93 1.48 ± 0.41 0.07
v. NG108-15 21 6 0.13 0.17 ± 0.91 0.87
v. OK 21,22 6 0.62 0.99 ± 0.73 0.27
v. α2C10 23 6 0.80 1.04 ± 0.45 0.10
v. α2C2 23 6 0.40 0.48 ± 0.65 0.50
v. α2C4 23 6 0.70 0.94 ± 0.52 0.16
v. BE(2)-C 6 6 0.98* 1.38 ± 0.18 0.01
Correlation coefficient values (r) were generated by comparing pKi values from Table 1 with previously published values for one-site models using 
Pearson correlation analysis (GraphPad Prism). The slope of the linear regression line is also included. Correlations were considered significant (*) 
if p ≤ 0.05.Page 3 of 12
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responses were also tested in this new cell line to confirm
that α2A-AR function had not been altered by the expres-
sion of the β2-AR (Table 1).
Chronic 300 nM EPI exposure induces α2A-AR 
desensitization only in SH-SY5Y cells transfected with 
functional β-AR
To determine whether the presence of the β-AR influences
α2A-AR signaling, the ability UK14,304 to inhibit forsko-
lin-stimulated cAMP accumulation was evaluated after
wildtype (wt) and SHβ2AR4 cells were exposed to vehicle
or the indicated concentration of agonist for 16–24 hr. Wt
SH-SY5Y cells (Fig 3A) require a 30-fold higher concentra-
tion of NE (30 μM) to desensitize the α2A-AR signal than
SHβ2AR4 cells (1 μM; Fig 3B). Both the potency (-Log
EC50 (M): 5.2 ± 0.1) and efficacy (Imax (%): 17.0 ± 1.6; P <
0.05 Fig. 3A) of UK14,304 were reduced by 30 μM NE
compared to vehicle treatment in wt cells (-7.6 ± 0.2 M
and 43.2 ± 6.8%); modest concentrations of NE (1 μM)
and EPI (300 nM) are insufficient to alter the α2A-AR sig-
nal in the wt SH-SY5Y cell line. In contrast, chronic treat-
ment of the β-AR-expressing SHβ2AR4 cells with 300 nM
RT-PCR Products obtained from SH-SY5Y RNA using α2-AR subtype selective primersFigure 2
RT-PCR Products obtained from SH-SY5Y RNA using α2-AR subtype selective primers. RT-PCR experiments were performed as described in 
"Methods" using primer pairs recognizing α2C10/C4 (corresponding to α2A and α2C) and α2C4 (corresponding to α2C) gene products (Table 3). The reac-
tions amplified fragments of the expected size from each set of primers. α2C10/C4 primers amplified 233 bp products from SH-SY5Y mRNA that were 
sensitive to digestion by BglII (specific for the α2A product). Restriction digestion with BstXI of the 630 bp product of α 2C4 primer amplification gave 
three fragments of 271, 225 and 78 bp. All reactions were performed in the presence (+) or absence (-) of reverse transcriptase (RT) to rule out the pos-
sibility of DNA contamination. Lane M designates the 100 bp ladder; the 500 bp fragment is indicated by an arrow in each panel.
Reversal of the inhibitory effect of UK 14,304 on forskolin-stimulated cAMP accumulationFigu e 1
Reversal of the inhibitory effect of UK 14,304 on forskolin-stimu-
lated cAMP accumulation. Yohimbine significantly antagonized the 
ability of UK14,304 (30 nM) to inhibit cAMP accumulation using an 
unpaired Student's t-test (GraphPad Prism, San Diego, CA), while the α2B/
C-selective antagonist, ARC-239, had no effect. The results represent the 
mean ± S.E. of 2–9 experiments, performed in duplicate.Page 4 of 12
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UK14,304 potency (-Log EC50 (M): Vehicle 6.9 ± 0.2; EPI
6.3 ± 0.2) and efficacy (Imax (%): Vehicle 68.2 ± 5.4; EPI
49.3 ± 10.4; p < 0.05; Fig. 3B). Unlike EPI, which co-acti-
vates both ARs, NE, at the concentrations employed acti-
vates only α2A-ARs and does not alter α2A-AR signaling.
We concluded that the difference in α2-AR signaling fol-
lowing EPI treatment between the transfected and wt SH-
SY5Y was attributable to the presence of functional β2-
ARs, respectively. To ensure that the vector was not
responsible for the observed difference between the wt
and SHβ2AR4 cells, similar experiments were conducted
in SH-SY5Y cells transfected with the vector alone (minus
the β2-AR gene). These vector only-expressing clones
Pretreatment with a modest concentration of EPI produces α2A-AR desensitization in SH-SY5Y cells only when the β2-AR is p sentFigure 3
Pretreatment with a modest concentration of EPI produces α2A-AR desensitization in SH-SY5Y cells only when the β2-AR is present. 
Wild-type SH-SY5Y cells (A), cells expressing recombinant β2-AR (SHβ2AR4, B and D), or SH-SY5Y cells expressing the vector alone (C) were pre-
treated 16–24 hr with any or all of the following: EPI (300 nM), NE (1 μM or 30 μM), EPI + Prop (30 nM), Prop (30 nM) alone or vehicle (0.1 mM ascor-
bate). Following pretreatment, the ability of UK14,304 to inhibit forskolin-stimulated cAMP accumulation was evaluated. A) Neither chronic EPI nor 1 μM 
NE pretreatments were sufficient to alter the α2A-AR signal (n = 6) in native SH-SY5Y cells. The α2A-AR signal in these cells desensitized only when 
exposed to higher agonist concentrations (30 μM NE, n = 3; 100 μM EPI, n = 3, data not shown). B) Unlike native SH-SY5Y cells, pretreatment with 300 
nM EPI is sufficient to desensitize the α2A-AR signal in SHβ2AR4 cells (n = 6; p < 0.05). NE (1 μM), acting predominantly at α2A-AR with little affinity for the β2-AR, does not produce α2A-AR desensitization. C) In SH-SY5Y cells transfected with the vector alone, neither EPI nor NE pretreatments altered α2A-AR 
signal (n = 4).D) Addition of propranolol (30 nM) prevents EPI-induced α2A-AR desensitization, suggesting a β2-AR-dependent process (# p < 0.05 as com-
pared to EPI treatment).
Table 3: Molecular characteristics of α2-AR RT-PCR products
PCR Product Primer: Receptor Expected size (bp) Restriction Enzyme Digestion Products (bp)
α2A/C-AR α2C10/C4 α2A 233 BglII 117 (2)α2C 233 SacI 153, 80α2C-AR α2C4 α2C 630 BstXI 271,225,78Page 5 of 12
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as the parent SH-SY5Y cells did (Fig. 3C).
To validate the importance of the β2-AR in the desensitiza-
tion of the α2-AR signal, we included the β-AR selective
antagonist propranolol (30 nM) with the chronic 300 nM
EPI treatment. Addition of propranolol blocks EPI-
induced α2A-AR desensitization resulting in UK14,304
concentration-response curves indistinguishable from
control (-Log EC50 (M) for EPI + Prop 6.7 ± 0.1; Imax (%)
for EPI + Prop 67.9 ± 0.4; p < 0.05; Fig. 3D). Propranolol
treatment alone did not alter UK14,304 potency or effi-
cacy.
β2-AR signal is desensitized following exposure to 300 nM 
EPI
To ensure that the β2-AR is functioning properly following
catecholamine treatment, we evaluated the ability of ISO
to stimulate cAMP accumulation over basal in SHβ2AR4
cells. The β2-AR signal is desensitized following chronic
EPI but not NE treatment, consistent with the fact that NE
has a low affinity for the β2-AR. Inclusion of propranolol
(30 nM) inhibited EPI-induced β2-AR desensitization (p <
0.05; Fig. 4), but had no effect in the absence of EPI.
Chronic EPI-induces down-regulation of the α2A-AR in 
SHβ2AR4, but not wt SH-SY5Y cells
Our study in BE(2)-C cells suggests that β2-AR-inducedα2A-AR desensitization following long-term EPI exposure
is due in part to down-regulation of the α2-ARs. To deter-
mine if the same mechanism is responsible for the EPI-
induced α2A-AR desensitization in SHβ2AR4 cells, changes
in α2A-AR expression following catecholamine treatment
were evaluated. Specific binding was measured with a sin-
gle concentration of radioligand. We, and others, have
shown that this is sufficient for accurate assessment of
changes in receptor number for the α2A-AR [9,15].
Chronic exposure of SHβ2AR4 cells to 300 nM EPI down-
regulates the α2A-ARs by 20% (p < 0.05; Fig. 5). The α2A-
AR down-regulation in this cell line, as in BE(2)-C cells,
requires β2-AR co-activation since loss of α2A-ARs is pre-
vented when 30 nM propranolol is included with EPI.
Down-regulation of the α2A-AR is not observed following
chronic activation of α2A-AR alone by 1 μM NE. Further,
300 nM EPI does not alter the expression of α2A-AR in wt
SH-SY5Y cells as compared to vehicle-treated cells (% of
vehicle: 88.6 ± 25.9; n = 2) consistent with a lack of α2A-
AR desensitization. Hence, it can be concluded that
chronic EPI treatment induces a loss of α2A-AR response
via β2-AR-dependent down-regulation of α2A-ARs in
SHβ2AR4, but not in wt SH-SY5Y cells.
Chronic EPI, but not NE, treatment desensitizes the β2-AR signal in SHβ2AR4 cellsFigure 4
Chronic EPI, but not NE, treatment desensitizes the β2-AR signal 
in SHβ2AR4 cells. SHβ2AR4 cells were treated for 16–24 hr with the 
vehicle (ascorbate, 1 μM), EPI (300 nM), NE (1 μM), EPI + Prop (30 nM), 
or Prop (30 nM) alone. Intact cells were assessed for ISO-stimulated (250 
nM) cAMP accumulation. Chronic 300 nM EPI (n = 6; *P < 0.05), but not 1 
μM NE (n = 3), pretreatment desensitized the β-AR response to ISO com-
pared to the corresponding vehicle-treated control. The β-AR antagonist 
propranolol blocked EPI-induced β2-AR desensitization. Data represent 
mean ± S.E. of at least 3 independent determinations; comparisons were 
made by ANOVA with Dunnett's post-hoc test.
Chronic 300 nM EPI down-regulates α2A-AR in β2-AR-trans-fected, but not native, SH-SY5Y cellsFigure 5
Chronic 300 nM EPI down-regulates α2A-AR in β2-AR-trans-
fected, but not native, SH-SY5Y cells. Wt SH-SY5Y or SHβ2AR4 cells 
were incubated for 16–24 hr with vehicle (ascorbate, 0.1 mM), 1 μM NE, 
300 nM EPI, EPI + Propranolol (30 nM), or 30 nM Propranolol alone. Cell 
membrane homogenates were generated as described in Methods. Specific 
binding (8084 ± 609 cpm/mg protein in vehicle-treated cells) was calcu-
lated by subtracting the binding of a single concentration of radioligand (2 
nM) in the presence of phentolamine (10 μM) from the binding in its 
absence. Unlike in native cells, chronic EPI treatment reduced α2A-AR lev-
els as compared to vehicle (*p < 0.05); inclusion of propranolol blocked 
the EPI-induced α2A-AR down-regulation (#p < 0.05 as compared to EPI 
treatment) in SHβ2AR4 cells. Data represent mean ± S.E., n = 2–4; com-
parisons were made by ANOVA with Tukey's post-hoc test.Page 6 of 12
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in whole cells but instead enhances GRK2 and GRK3 
expression at the membrane in SHβ2AR4 cells
We previously established that EPI-induced α2A-AR desen-
sitization and down-regulation in BE(2)-C cells is medi-
ated via β2-AR-dependent GRK3 up-regulation [15].
Therefore, GRK3 levels in whole cell SHβ2AR4 lysates
were evaluated following 24 hr catecholamine treatments.
Chronic EPI exposure altered neither GRK3 nor GRK2 lev-
els in the transfected SH-SY5Y cell line (Table 4). There-
fore, unlike results in BE(2)-C cells, increases in whole cell
GRK3 levels do not contribute to the modest α2A-AR
desensitization or down-regulation observed in the
SHβ2AR4 cells.
Although GRK3 levels in whole cell lysates remain unal-
tered in SHβ2AR4 cells, it is not known whether GRK3
recruitment to the membrane is regulated via chronic EPI
treatment in that cell line. Since GRK2 and GRK3 have
been shown to regulate α2A-AR signaling [10], we wanted
to determine whether the membrane recruitment of either
GRK isoform was changed following chronic EPI exposure
in SHβ2AR4 cells. GRK2 and GRK3 are cytosolic proteins
that anchor to the membrane via interaction with free Gβγ
subunits; thus both kinases translocate from the cytosol to
the membrane to regulate receptor signaling upon activa-
tion. Taking this characteristic of GRK2 and GRK3 into
account, the levels of both kinases in membrane fractions
following chronic EPI exposure were evaluated. SHβ2AR4
cells exhibit an increase in membrane-associated GRK2
and GRK3 with 24 hr EPI treatment compared to vehicle
(P < 0.05; Fig. 6). In SHβ2AR4 cells, the same propranolol
concentration (30 nM) that inhibited EPI-induced α2A-AR
desensitization and down-regulation also attenuated EPI-
induced increase in GRK2 and GRK3 content in the mem-
brane fraction (P < 0.05; Fig. 6). In contrast, no increased
translocation of GRKs by EPI treatment was observed in
wt SH-SY5Y cells that do not express β2-ARs. Therefore,
this increased GRK2 and GRK3 translocation to the mem-
brane following prolonged EPI treatment in SHβ2AR4
cells is β2-AR dependent.
Discussion
The major finding of the present study is the confirmation
(using a different approach) that sensitivity of α2A-AR to
desensitization following exposure to relatively low levels
of epinephrine is significantly increased in cells expressing
both α2A- and β2-AR. The first evidence for this was
recently reported in a human neuronal cell line endog-
Chronic 300 nM EPI enhances expression of GRK3 and GRK2 at the membrane of SHβ2AR4 cells via β2-AR-depend-ent me hanisFigur  6
Chronic 300 nM EPI enhances expression of GRK3 and GRK2 at 
the membrane of SHβ2AR4 cells via β2-AR-dependent mecha-
nism. Wildtype SH-SY5Y (Wt SH) and SHβ2AR4 cells were subjected to 
catecholamine treatment in the presence or absence of 30 nM pro-
pranolol. Isolation of the membrane fraction and immunoblotting for 
GRK2 and GRK3 was conducted as described in Methods. EPI exposure 
significantly increased the level of GRK3 and GRK2 expressed in the mem-
brane fractions from SHβ2AR4 cells compared to vehicle-treated controls 
(*P < 0.05; n = 3). Inclusion of propranolol (P) with EPI treatment pre-
vented the increased translocation of both GRK isoforms (#P < 0.01 as 
compared to EPI treatment), while propranolol treatment alone was with-
out effect. In contrast, EPI failed to increase mobilization of GRK to the 
plasma membrane of wt SH cells (n = 4–7). Data represent mean ± S.E.; 
comparisons were made by ANOVA with Tukey's post-hoc test.
Table 4: Total GRK levels are unaltered in SHβ2AR4 cells with 
catecholamine treatment.
Catecholamine Treatment*
EPI EPI+P Prop NE
GRK3 94 ± 8 (7) 84 ± 15 (7) 80 ± 20 (7) 84 ± 20 (5)
GRK2 101 ± 10 (7) 97 ± 16 (7) 105 ± 14 (7) 83 ± 23 (4)
SHβ2AR4 cells were treated with vehicle (0.1 mM ascorbate), EPI (300 
nM), propranolol, EPI + propranolol, or 1 μM NE for 24 hr. 
Approximately 25 μg of whole cell lysate from each treatment group 
was resolved by SDS-PAGE through a 10% gel. Immunoreactive bands 
were normalized to the GAPDH loading control and the GRK/
GAPDH ratio was calculated.* Data represent % of expression levels 
noted in vehicle-treated cells (mean ± s.e.m.); number of independent 
determinations is given in parentheses following the values.Page 7 of 12
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BE(2)-C cells desensitized after chronic EPI (300 nM), but
not NE (1 μM), treatment [15]. Interestingly, the α2A-AR
responsiveness in SH-SY5Y cells (an alternative human
neuroblastoma cell line that does not express β-ARs) is
not desensitized after chronic treatment with 300 nM EPI
or 1 μM NE (Fig. 3).
Obviously, the difference in α2-AR sensitivity to lower
concentrations of EPI could be due to several factors,
including differences in the α2-AR subtypes expressed in
each cell line. Since it is difficult to demonstrate with great
certainty what α2-AR subtypes are present in a given cell or
tissue by biochemical or pharmacological means only, we
took a molecular approach to ascertain which subtypes
might potentially be expressed based on the presence of
mRNA encoding each subtype. SH-SY5Y cells contained
mRNA for α2A- and α2C-ARs (Fig. 2). As we noted and as
reported by others [25], no evidence for α2B mRNA was
found. This was further confirmed by Northern blot anal-
ysis (data not shown). Initially, total RNA isolated from
SH-SY5Y cells did not produce the α2A-AR PCR products
using the antisense primer selective for α2A-AR previously
described [30]. Instead α2A-AR RT-PCR product was
obtained only with poly(A) mRNA. However, employing
poly(A)-enriched mRNA in the RT-PCR did not yield an
α2B-AR RT-PCR product. Parsley et al. [25]) identified onlyα2C-AR mRNA using total RNA isolated from SH-SY5Y
cells; this observation may reflect the limitation associ-
ated with the α2A-AR primers used for RT-PCR of total
RNA, similar to what we encountered.
The rank order binding affinity of the various agonists and
antagonists tested is in agreement with that previously
reported in cells expressing recombinant [3,28,31] or
native α2A-ARs [26,32]. When we compared apparent pKi
values for various α2-AR agonists and antagonists against
binding to [3H]rauwolscine in SH-SY5Y membrane
homogenates with previously reported values, we saw a
correlation only with those cells that expressed α2A-ARs
(Table 2). Another means of distinguishing between vari-
ous α2-AR subtypes involves comparing the prazosin/
oxymetazoline (OXY) or OXY/yohimbine affinity ratios
(Table 1; [4]). Prazosin/OXY (74.4) and OXY/yohimbine
(1.95) ratios were within the range reported for native and
recombinant α2A-ARs, and differ by at least 10-fold from
values reported for α2C-AR (from [4]). The agonist potency
series in SH-SY5Y cells also most closely parallels that
reported for the α2A [26-28,32]. The inhibitory effect ofα2-AR agonists on cAMP production in SH-SY5Y cells is
readily reversed in a concentration-dependent fashion by
the antagonist yohimbine (Fig. 1); the failure of the selec-
tive α2B/C antagonist ARC-239 to antagonize UK 14,304 is
consistent with activation of α2A-ARs in SH-SY5Y cells.
Therefore, our results strongly support the designation of
the functional α2-AR in SH-SY5Y cells as α2A.
The present study supports our previous findings that pre-
treatment with a modest EPI concentration readily desen-
sitizes the α2A-AR signal in the presence, but not in the
absence, of the β2-AR. This conclusion is based on several
results. First, in wt SH-SY5Y cells (no β2-AR), the α2A-AR
signal is not desensitized following 24 hr treatment with
modest concentrations of EPI or NE (300 nM and 1 μM,
respectively). Instead wt cells required chronic exposure to
supra-physiological concentrations of catecholamines (30
μM NE and 100 μM EPI; data not shown) for desensitiza-
tion of the α2A-AR signal; supporting the fact that α2A-ARs
do not desensitize and/or down-regulate readily in
response to low to moderate levels of EPI. Second, 300
nM EPI induces α2A-AR desensitization only in SHβ2AR4
cells which express functional β2-AR. Finally, EPI-gener-
ated waning of the α2A-AR response is not observed in
transfected cells expressing the pcDNA plasmid vector
minus the β2-AR gene. This observation suggests that
introduction of the β2-AR, and not the vector, is responsi-
ble for the difference in the α2A-AR signal between wt and
SHβ2AR4 cells exposed chronically to modest EPI concen-
trations.
As previously observed in BE(2)-C cells [15], desensitiza-
tion of α2A-AR signal with 24 hr EPI exposure is due, in
part, to down-regulation of the receptor in SHβ2AR4 cells.
Chronic co-activation of both α2A- and β2-AR is required
for desensitization and down-regulation of the α2A-AR in
SHβ2AR4 cells as indicated by the following results. First,
300 nM EPI, but not 1 μM NE, produces α2A-AR desensi-
tization and down-regulation in the recombinant cell
line. Lands et al. [33] established that EPI has equal affin-
ity for α2A- and β2-AR while NE has a higher affinity for theα2-AR than β2-AR; therefore, EPI activates both α2A- andβ2-ARs simultaneously while NE activates the α2A-AR
alone. It is evident that the modest EPI concentration
readily activates the β2-AR since chronic pretreatment
with 300 nM EPI, but not 1 μM NE, desensitized the β2-AR
response. Second, the inclusion of the β2-AR blocker pro-
pranolol prevented EPI-induced α2A-AR desensitization
and down-regulation in β2-AR-transfected SH-SY5Y cells.
This propranolol concentration (30 nM) is sufficient to
prevent EPI activation of β2-AR as indicated by the inhibi-
tion of EPI-induced β2-AR desensitization.
Although chronic EPI treatment desensitized and down-
regulated α2A-AR in both BE(2)-C and SHβ2AR4 cells, sev-
eral differences were observed. First, a more profound loss
of efficacy is observed following 24 hr EPI exposure in
BE(2)-C cells as compared to SHβ2AR4 cells. The maximal
inhibition of forskolin-stimulated cAMP accumulation by
UK14,340 was reduced 54% in BE(2)-C, but only 27% inPage 8 of 12
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greater down-regulation of α2A-ARs observed in BE(2)-C
versus SHβ2AR4 cells most likely accounts for the greater
change in efficacy: in SHβ2AR4, chronic EPI treatment
produces a 20% loss of α2A-ARs while in BE(2)-C cells,
there is a 60% α2A-AR down-regulation (Fig. 5). This more
profound α2A-AR desensitization and down-regulation
observed in BE(2)-C is mediated via the up-regulation of
GRK3 [15]. The lack of GRK3 up-regulation in the
SHβ2AR4 cells is the second major difference between the
two cell lines. At present, it is unknown what prompts
GRK3 up-regulation in BE(2)-C cells but not in the
SHβ2AR4 cells. However, we have observed that ERK1/2
activation is required for this induction of GRK3 follow-
ing chronic exposure of BE(2)-C cells to EPI [16]. Moreo-
ver, while α2A-ARs do not readily activate this pathway in
neuronal cells, and β-AR activation by ISO can activate
ERK1/2 at high concentrations, we have observed that
ERK1/2 activation by EPI at concentrations that up-regu-
late GRK3 appears to require the simultaneous activation
of both α2A- and β2-ARs. Conversely, the inability of trans-
fected β-ARs to prompt ERK1/2 activation in SH-SY5Y
cells could explain the lack of GRK3 up-regulation in
SHβ2AR4 cells.
Even though total GRK3 levels are unaltered, GRKs play a
role in β2-AR-regulated α2A-AR signaling in SHβ2AR4 cells
as indicated by several results. First chronic EPI treatment
enhances localization of GRK2 and GRK3 to the mem-
brane. As indicated previously, translocation of these two
cytosolic kinases to the membrane is required for phos-
phorylation and subsequent desensitization of its recep-
tor substrate, which in this study is the α2A-AR. Second,
addition of propranolol attenuated EPI-mediated translo-
cation of both GRK isoforms. This same propranolol con-
centration also inhibited α2A-AR desensitization and
down-regulation as discussed above. Therefore, β2-AR co-
activation with α2A-AR is required for enhanced GRK2 and
GRK3 translocation to the membrane and subsequent
α2A-AR desensitization and down-regulation.
Translocation of both GRK2 and GRK3 to the membrane
following chronic EPI treatment in SHβ2AR4 cells differs
from the selective translocation of GRK3 (but not GRK2)
observed in BE(2)-C cells following the same treatment
(unpublished observations). The selective GRK3 up-regu-
lation in BE(2)-C cells could account for the enhanced
GRK3 levels at the membrane in these cells since in a pre-
vious study increase in total GRK2 levels promoted
increased GRK2 expression at the membrane [34]. It is
unknown at present why chronic EPI treatment translo-
cates both GRK2 and GRK3 in SHβ2AR4 cells, and not in
BE(2)-C cells. A possible explanation for the difference in
the GRK isoform translocation between the two cell lines
is differences in the β subunit expressed and/or released
upon EPI exposure. GRK2 and GRK3 require the βγ subu-
nit of the G proteins to anchor to the membrane but
GRK2 and GRK3 exhibit distinct binding preferences for
individual β subunits [35]. The β3 isoform preferentially
binds GRK3 but not GRK2, whereas β1 and β2 bind equally
to both GRK3 and GRK2 [35,36].
Conclusion
Based on results obtained in this series of experiments, we
conclude that exposure to modest EPI concentrations
readily desensitizes and down-regulates α2A-ARs in the
presence, but not in the absence, of a functional β-AR. The
β-AR-dependent down-regulation of α2A-ARs is modu-
lated via GRKs. In BE(2)-C cells, chronic co-activation of
β- and α2A-AR prompts enhanced expression of GRK3, but
not GRK2, in whole cells [15] and membrane fractions. In
contrast, EPI pretreatment of SH-SY5Y cells transfected
with functional β2-ARs does not increase either GRK3 or
GRK2 expression per se, but does increase translocation of
GRK2 and GRK3 to the plasma membrane. Like α2A-AR
desensitization and down-regulation, this translocation
of GRK2 and GRK3 in SHβ2AR4 cells is β-AR-dependent
and thus presents an alternate mechanism for the regula-
tion of the α2A-ARs by β-ARs.
Methods
Materials
The following drugs were purchased or obtained from the
indicated sources: (-) epinephrine (EPI), (±)norepine-
phrine (NE), sodium ascorbate, UK14,304 (Sigma-
Aldrich, St. Louis, MO.); cell culture media (Gibco, Grand
Island, NY); fetal bovine serum (Atlanta Biologicals, Nor-
cross, GA); and antibiotics (Mediatech, Inc., Herndon,
VA). GRK2 (C-15) and GRK3 (C-14) primary antibodies
and horseradish peroxidase-conjugated secondary anti-
body (Santa Cruz Biotechnology, Inc., Santa Cruz, CA);
anti-glyceraldehyde-3-phosphate dehydrogenase
(GADPH, Research Diagnostics, Inc., Flanders, NJ).
Cell culture
SH-SY5Y (passages 37–55) human neuroblastoma cells
(Dr. Robert A. Ross, Fordham University, Bronx, NY) were
maintained in a humidified atmosphere (6% CO2:94%
air) in a 1:1 mixture of Eagle's minimum essential
medium with non-essential amino acids and Ham's F-12
that contains 10% fetal bovine serum, 100 U/ml penicil-
lin G and 0.1 mg/ml streptomycin sulfate. Plates of cells
greater than 60% confluence were used throughout the
study.
Transfection
Plasmid cDNA with the human β2-AR gene (provided by
Dr. Brian Knoll; University of Houston, Houston, TX) or
vector alone was stably transfected into SH-SY5Y cells
with the fuGENE 6 Transfecting Reagent (Roche). TenPage 9 of 12
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mL of G418 and maintained in media containing 600 μg/
mL of G418. SHβ2AR4 was selected for use in all experi-
ments because it expressed similar levels of β2-ARs as that
expressed natively in BE(2)-C cells; SHβ2AR4 expressed
14.78 ± 4.19 fmol/mg protein while BE(2)-C express 18.5
± 6.2 fmol/mg protein [15]. This β2-AR level remained
consistent to passage 12 in SHβ2AR4 cells. After passage
12, SHβ2ARs neither expressed β2-ARs nor maintained
resistance to G418, suggesting that the cells no longer
expressed the transfected plasmid.
RNA isolation and RT-PCR
Total RNA was isolated from several different passages of
freshly harvested SH-SY5Y cells by the guanidinium iso-
thiocyanate/phenol-chloroform extraction method [37].
Total RNA concentrations were determined by UV spec-
troscopy; integrity of each isolate was determined by elec-
trophoresis through a 1% agarose gel in the presence of
0.01 M sodium phosphate buffer. Poly(A) mRNA was iso-
lated using a Dynabead oligo(dT)25 Kit (Dynal, Oslo, Nor-
way) and was used for RT-PCR reactions. Each RT reaction
(20 μL) contained 5–10 μg total or poly(A) RNA preincu-
bated with 5 ng/μL oligo(dT)12–18, for 10 min at 70°C.
The reaction mixture contained 80 μM each of deoxynu-
cleotides (dATP, dCTP, dGTP and dTTP), RT buffer (50
mM Tris-HCl, pH 8.3, 75 mM KCl, 3 mM MgCl2), and 5
mM dithiothreitol, and was preincubated for 2 min at
42°C before the addition of Moloney Murine Leukemia
Virus reverse transcriptase (200 U/μl) for 60 min at 42°C;
a 5 min incubation at 95°C terminated the reactions.
ODNs [29,30] corresponded to sequences for the various
human α2-AR (α2A antisense: 5'-AGA CGA GCT CTC CTC
CAG GT-3'; sense: 5'-AAA CCT CTT CCT GGT GTC TC-3'),
α2A/2C-(antisense: 5'-GTG CGC TTC AGG TTG TAC TC-3';
sense: 5'-AAA CCT CTT CCT GGT GTC TC-3'), or α2C-AR
(antisense: 5'-CGT TTT CGG TAG TCG GGG AC-3'; sense:
5'-GTG GTG ATC GCC GTG CTG AC-3'). The contents of
each RT reaction tube were diluted to a final volume of 50
μL with 10% DMSO, 80 μM each of dATP, dCTP, dGTP
and dTTP, 8 μM each of the appropriate sense/antisense
primer pair, 1.5 mM MgCl2, and magnesium free buffer
[containing 10 mM Tris-HCl (pH 9.0), 0.1% Triton X-100,
50 mM KCl] in sterile distilled water. Reaction mixtures
were overlayed with mineral oil and subjected to a hot
start for 5 min at 95°C. DNA polymerase (2.5 U taq, 5 U/
μl, Promega, Madison, WI) was added to each reaction
tube after the hot start, and the tubes were subjected to a
PCR reaction of 30 cycles in a thermal cycler (MJ Research
Inc., Watertown, MA) for 1 min at 94°C, 1.5 min at 55°C,
and 2 min at 72°C with a final elongation step at 72°C for
7 min. Reaction products were separated by electrophore-
sis through 2% agarose gels and visualized by ethidium
bromide staining. PCR products were isolated from the
gel using a DNA extraction kit (Amicon Inc., Bedford,
MA). Identity of the purified PCR products was confirmed
by their susceptibility to digestion with restriction
enzymes specific for each reaction product (see Table 1;
[30]).
cAMP accumulation
To determine the effects of α2-AR agonists on forskolin-
induced cAMP accumulation, intact cells were incubated
for 5 minutes at 37°C in HBSS buffer (in mM): NaCl
(137), KCl (5), Na2HPO4 (0.6), KH2PO4 (0.4), NaHCO3
(4), D-glucose (6), MgCl2 (0.5), MgSO4 (0.4) and CaCl2
(1), containing the phosphodiesterase inhibitor IBMX
(0.5 mM). In some experiments, antagonists also were
included in this step. To prohibit oxidation, sodium
ascorbate (0.11 mM) was included when assaying cate-
cholamines. Upon addition of forskolin (10 μM) and ago-
nist, assay tubes were incubated for an additional 10 min
at 37°C. Removing the tubes to a boiling water bath for 5
min terminated the assay. All assays were performed in
duplicate in a total volume of 0.5 ml. After boiling, sam-
ples were centrifuged for 5 min at 14000 × g, and cAMP
levels from the supernatant fractions were determined in
a [3H]cAMP (0.8 pmol) binding assay as previously
described [38]. β-AR-mediated stimulation of cAMP accu-
mulation was performed in the same manner except that
forskolin was not included in the assay mixture. Forskolin
(10 μM) stimulated cAMP accumulation to 587 ± 88
pmol/mg protein (n = 46), 15-fold over basal levels (40.5
± 2 pmol/mg protein).
Receptor binding
Preparation of cell membranes
Cells were homogenized in 20 volumes of Tris-HCl buffer
(50 mM, pH 7.4) containing NaCl (100 mM), Na2 EDTA
(1 mM) and PMSF (0.1 mM), and the membranes sedi-
mented by centrifugation for 30 minutes at 34000 × g at
4°C. Pellets were resuspended in 0.32 M sucrose, and
aliquots of the membrane fractions were stored frozen (-
80°C) until use.
Saturation experiments
The level of α2-ARs in SH-SY5Y cell membranes (0.5 mg/
ml) was determined with various concentrations of
[3H]rauwolscine (60–80 Ci/mmol, 0.3 – 12 nM) in a total
volume of 1–2 ml in potassium phosphate buffer (50
mM, pH 7.4) containing MgSO4 (5 mM) at 37°C for 45
min. Thereafter, 2 ml Tris-HCl (5 mM, pH 7.4, 4°C) was
added to the homogenate to terminate the binding reac-
tion and the contents of the tubes was filtered over #32
glass fiber filter strips (Schleicher & Schuell, Keene, NH)
using a PHD cell harvester (Cambridge Technology, Cam-
bridge, MA). The reaction tubes and the filter strips were
rinsed twice with a further 2–3 ml of buffer. Levels of radi-
oactivity were determined by scintillation spectroscopy inPage 10 of 12
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were performed in triplicate, and specific binding was
determined by subtracting the binding in the presence of
yohimbine or phentolamine (10 μM; nonspecific) from
the binding in its absence.
Previously we have shown that agonist treatments do not
alter the Kd of the ligand for the α2-AR [15]. Therefore, lev-
els of α2-ARs in SHβ2AR4 cell membranes (0.1 – 0.2 mg/
mL) were determined using a single concentration (2 nM)
of either [3H]rauwolscine or [3H]RX821002 following cat-
echolamine treatment.
β2-AR binding was performed with [3H]CGP-12177. For
saturation studies, cell membranes (0.5 mg/mL) were
incubated with [3H]CGP-12177 (0.2 to 40 nM) in Tris-
HCl buffer (50 mM, pH 7.5) containing MgCl2 (0.5 mM)
at 37°C for 30 min. Specific binding was determined by
subtracting the binding in the presence and absence of
propranolol (1 μM).
Competition experiments
Cell membrane fractions were incubated as described
above except that the concentration of [3H]rauwolscine
was fixed (1 nM), and various (4–9) concentrations of
unlabeled drugs were included.
Immunoblotting
Membrane proteins were separated from cytosolic pro-
teins by centrifugation, were resolved by SDS-PAGE
through 10% gels and relative levels of GRK2 and GRK3
determined by immunoblotting as described previously
[15]. Briefly, proteins were transferred to PVDF mem-
brane, blocked with 5% nonfat dried milk in PBS contain-
ing 0.1% Tween (PBS/T) and incubated overnight at 4°C
with dilutions of a rabbit polyclonal antibody directed
against GRK2 (1:1000), GRK3 (1:1000), or both GRK2
and GRK3 (GRK2/3; 1:1000; wt SH-SY5Y). Blots were sub-
jected to 4 washes before incubating for 60 min at room
temperature with a goat anti-rabbit horseradish peroxi-
dase-conjugated secondary antibody (1:2000) in PBS/T.
Immunoreactive bands were visualized by enhanced
chemiluminescence (Amersham Corp., Arlington
Heights, IL or Santa Cruz Biotechnology, Inc., Santa Cruz,
CA). The intensity of each immunoreactive band was
determined using a Nucleovision Imaging Workstation
(Nucleotech Corp., San Carlos, CA), and normalized to
the GAPDH loading control (1:5000).
Protein determination
Bovine serum albumin was used as a standard in the
determination of protein levels in intact cells and cell
membranes as described [39].
Data analysis
Kd, Bmax, IC50 and LogEC50 values were determined by
nonlinear regression analysis using GraphPad Prism
(GraphPad Software http://www.graphpad.com). The Ki
values were calculated according to the Cheng-Prusoff
equation [40] in which Ki = (IC50)/(1+S), where S = [con-
centration of radioligand]/[KD of radioligand]. Compari-
sons between groups were made by two-way Student's t-
tests or ANOVA and Tukey's or Dunnett's post hoc test
(where appropriate; GraphPad Software, San Diego, CA),
and groups were considered significantly different if p ≤
0.05.
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